Morgenthaler has particular expertise in family andfounder-owned transitions and corporate divestitures

Morgenthaler has particular expertise in family andfounder-owned transitions and corporate divestitures."I was attracted to Morgenthaler because of the quality of their people,disciplined strategy, commitment to the lower middle market and focus onpartnering with management to build the underlying value of businesses throughoperational and strategic enhancements," said Kevin Macdonald. Heis also a proven leader who can help us take our organization to the nextlevel." According to Stanley, Morgenthaler's Private Equity Team focuses on investingin profitable businesses in high-value manufacturing and business services inthe lower end of the middle market - with enterprise values of $25 million to$250 million. "He has an exceptional personal track record andinvestment history, with direct experience in our primary areas of focus. Most recently, he was a founder and managing partner of MonitorClipper Partners, a $2 billion middle market investment firm based inCambridge, MA.Macdonald was also a founding member of The Clipper Group, a$1.5 billion investment firm affiliated with Credit Suisse First Boston."Kevin is a world-class private equity professional and we are privileged tohave him join us," said Al Stanley, co-managing partner of Morgenthaler'sPrivate Equity Team.

Macdonald joins Morgenthaler with more than 20 years of private equityexperience. Morgenthaler Appoints Kevin Macdonald as Co-Managing Partner of Private EquityTeamBOSTON, April 22 /PRNewswire/ -- Morgenthaler, a leading private equity andventure capital firm, today announced the appointment of Kevin Macdonald asco-managing partner of Morgenthaler's Private Equity Team().In his new role, Macdonald and co-managingpartner Al Stanley will oversee all aspects of Morgenthaler's private equityactivities including existing portfolio companies, new investments, strategyformulation and franchise development.Macdonald will be based in the firm'sBoston office. But Telfair seems to be a more natural point guard.  He has amazing passing ability and got great deal of experience this past season in Foye's absence.I don't have a problem with keeping both of them, but I don't think whoever gets the short end of the stick is going to want to stick around knowing they aren't the PG of the future. The starters for next year's squad as of today should look something like thisPG Randy FoyeSG Rashad McCantsSF Corey BrewerPF Kevin LoveC Al JeffersonSixth man Mike Miller (Ginobili-esque minutes)Seventh man Sebastian TelfairEighth man Craig SmithThey're still light years away from the playoffs, but that team should win 30-35 games. . Both make about the same amount of money and both look like they can run an offense.Foye is a little bigger and a better shooter, which makes me want to keep him more. Or Corey Brewer can start putting Miller in the sixth man role he's thrived in.I don't know if the Timberwolves are done making transactions this summer either. They've got a definite problem with the starting point guard situation.  Foye and Telfair are 24 and 23, respectively.

3 last year for that. I've always liked teams that play from the inside-out which is why I really like this pick. The Timberwolves can now take Kirk Snyder out of the starting lineup, and perhaps replace him with Mike Miller. 2 scorer behind Rudy Gay.  The Grizzlies aren't going to need him to be a high assist guy because they drafted Mike Conley, Jr at No. Taking advantage of its established trans-pacific network of scientific andindustry contacts, TOPICA has in-licensed its lead-product candidate,luliconazole, a topical antifungal agent that is already on the market inJapan.TOPICA is developing it for the treatment of tinea pedis (athlete'sfoot) and onychomycosis (nail and nail bed fungal infections).For moreinformation, please visit http:// PharmaceuticalsDaryl Messinger of WeissComm Partners, +1-415-946-1062,. In 2008, the U.S.prescription market for tinea pedis was $385 million equating to approximately22 million prescriptions.The topical prescription antifungal market has beendominated in recent years by generics due to the fact that a new prescriptionanti-fungal agent has been not been introduced into the market in over fiveyears.About TOPICA PharmaceuticalsTOPICA is a privately held, specialty pharmaceutical company, focused onlicensing, developing, and commercializing potent topical prescriptionproducts to treat the needs of patients with serious nail and skin conditions.